Positron emission tomography and molecular imaging

Heart

Volumn 94, Issue 3, 2008, Pages 360-367

  Knuuti, J ^a,c   Bengel, F M ^b  

^a UNIVERSITY OF TURKU   (Finland)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c TURKU PET CENTRE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EPHEDRINE DERIVATIVE; FLUORODEOXYGLUCOSE F 18; TRACER;

ANGIOCARDIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DISEASE COURSE; GENE THERAPY; HEART MUSCLE PERFUSION; HUMAN; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; STEM CELL;

CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; HUMANS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 39749193608     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2007.118992     Document Type: Review

References (66)

1. DiCarli MF, Hachamovitch R. New technology for noninvasive evaluation of coronary artery disease. Circulation 2007;115:1464- 80.
2. Wijns W. Anatomic-functional imaging by single-photon emission computed tomography/computed tomography as the cornerstone of diagnosis and treatment for coronary patients: a glimpse into the (near) future? J Am Coll Cardiol 2007;49:1068-70.
3. Ter-Pogossian MM. Positron emission tomography (PET). J Med Syst 1982;6:569-77.
4. Brunken BC, Schelbert HR. Positron emission tomography in clinical cardiology. Cardiol Clin 1989;7:607-29.
5. Lodge MA, Bengel FM. Methodology for quantifying absolute myocardial perfusion with PET and SPECT. Curr Cardiol Rep 2007;9:121-8.
6. Tillisch J, Brunken R,shall R, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986;314:884-8.
7. Knuuti J, Schelbert HR, Bax JJ. The need for standardisation of cardiac FDG PET imaging in the evaluation of myocardial viability in patients with chronic ischaemic left ventricular dysfunction. Eur J Nucl Med Mol Imaging 2002;29:1257-66.
8. Beanlands RS, Nahmias C, Gordon E, et al. The effects of beta-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: a double-blind, placebo-controlled, positron-emission tomography study. Circulation 2000;102:2070-5.
9. Stolen KQ, Kemppainen J, Ukkonen H, et al. Exercise training improves biventricular oxidative metabolism and left ventricular efficiency in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003;41:460-7.
10. Shah A, Schelbert HR, Schwaiger M, et al. Measurement of regional myocardial blood flow with N-13 ammonia and positron emission tomography in intact dogs. J Am Coll Cardiol 1985;5:92-100.
11. Bergmann SB, Fox K, Rand A, et al. Quantification of regional myocardial blood flow in vivo with H15-0. Circulation 1984;70:724-33.
12. Goldstein R, Mullani N,ani S, et al. Myocardial perfusion with rubidium-82. II: Effects of metabolic and pharmacologic interventions. J Nucl Med 1983;24:907-15.
13. Kaufmann PA, Gnecchi-Ruscone T, Yap JT, et al. Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with 150-labeled water and PET. J Nucl Med 1999;40:1848-56.
14. Pietila M, Malminiemi K, Ukkonen H, et al. Reduced myocardial carbon-11 hydroxyephedrine retention is associated with poor prognosis in chronic heart failure. Eur J Nucl Med 2001;28:373-6.
15. Bengel FM, Schwaiger M. Assessment of cardiac sympathetic neuronal function using PET imaging. J Nucl Cardiol 2004;11:603-16.
16. Le Guludec D, Cohen-Solal A, Delforge J, et al. Increased myocardial muscarinic receptor density in idiopathic dilated cardiomyopathy: an in vivo PET study. Circulation 1997;96:3416-22.
17. Higuchi T, Schwaiger M. Imaging cardiac neuronal function and dysfunction. Curr Cardiol 2006;8:131-8.
18. Naghavi M, Madjid M, Khan MR, et al. New developments in the detection of vulnerable plaque. Curr Atheroscler Rep 2001;3:125-35.
19. Bengel FM, Anton M, Richter T, et al. Noninvasive imaging of transgene expression by use of positron emission tomography in a pig model of myocardial gene transfer. Circulation 2003;108:2127-33.
20. Pither R. PET and the role of in vivo molecular imaging in personalized medicine. Expert Rev Mol Diagn 2003;3:703-13.
21. Hesse B, Tagil K, Cuocolo A, et al. EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology. Eur J Nucl Med Mol Imaging 2005;32:855-97
22. Bacharach SL, Bax JJ, Case J, et al. PET myocardial glucose metabolism and perfusion imaging: Part 1-Guidelines for data acquisition and patient preparation. J Nucl Cardiol 2003;10:543-56.
23. Schelbert HR, Beanlands R, Bengel F, et al. PET myocardial perfusion and glucose metabolism imaging: Part 2-Guidelines for interpretation and reporting. J Nucl Cardiol 2003;10:557-71.
24. Schelbert HR, Wisenberg G, Phelps ME, et al. Noninvasive assessment of coronary stenoses by myocardial imaging during pharmacologic coronary vasodilation. VI. Detection of coronary artery disease in human beings with intravenous N-13 ammonia and positron computed tomography. Am J Cardiol 1982;49:1197-207.
25. Gould KL, Goldstein RA, Mullani NA, et al. Noninvasive assessment of coronary stenoses by myocardial perfusion imaging during pharmacologic coronary vasodilation. VIII. Clinical feasibility of positron cardiac imaging without a cyclotron using generator-produced Rubidium-82. J Am Coll Cardiol 1986;7:775-89.
26. Yonekura Y, Tamaki N, Senda M, et al. Detection of coronary artery disease with 13N-ammonia and high-resolution positron-emission computed tomography. Am Heart J 1987;113:645-54.
27. Tamaki N, Yonekura Y, Senda M, et al. Value and limitation of stress thallium-201 single photon emission computed tomography: comparison with nitrogen-13 ammonia positron tomography. J Nucl Med 1988;29:1181-8.
28. Demer LL, Gould KL, Goldstein RA, et al. Assessment of coronary artery disease severity by positron emission tomography. Comparison with quantitative arteriography in 193 patients. Circulation 1989;79:825-35.
29. Go RT,wick TH, MacIntyre WJ, et al. A prospective comparison of rubidium-82 PET and thallium-201 SPECT myocardial perfusion imaging utilizing a single dipyridamole stress in the diagnosis of coronary artery disease. J Nucl Med 1990;31:1899-905.
30. Williams KA, Ryan JW, Resnekov L, et al. Planar positron imaging of rubidium-82 for myocardial infarction: a comparison with thallium-201 and regional wall motion. Am Heart J 1989;118:601-10.
31. Stewart RE, Schwaiger M, Molina E, et al. Comparison of rubidium-82 positron emission tomography and thallium-201 SPECT imaging for detection of coronary artery disease. Am J Cardiol 1991;67:1303- 10.
32. wick TH, Lafont A, Go RT, et al. Identification of recurrent ischemia after coronary artery bypass surgery: a comparison of positron emission tomography and single photon emission computed tomography. Int J Cardiol 1992;35:33-41.
33. Grover-McKay M, Ratib O, Schwaiger M, et al. Detection of coronary artery disease with positron emission tomography and rubidium 82. Am Heart J 1992;123:646-52.
34. Laubenbacher C, Rothley J, Sitomer J, et al. An automated analysis program for the evaluation of cardiac PET studies: initial results in the detection and localization of coronary artery disease using nitrogen-13-ammonia. J Nucl Med 1993;34:968-78.
35. Muzik O, Duvernoy C, Beanlands RS, et al. Assessment of diagnostic performance of quantitative flow measurements in normal subjects and patients with angiographically documented coronary artery disease by means of nitrogen-13 ammonia and positron emission tomography. J Am Coll Cardiol 1998;31:534-40.
36. Sampson UK, Limaye A, Dorbala S, et al. Diagnostic accuracy of rubidium-82 myocardial perfusion imaging with hybrid positron emission tomography/computed tomography (PET-CT) in the detection of coronary artery disease. J Am Coll Cardiol 2007;49:1052-8.
37. Bateman TM, Heller GV, McGhie AI, et al. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT. J Nucl Cardiol 2006;13:24-33.
38. Parkash R, deKemp RA, Ruddy TD, et al. Potential utility of rubidium 82 PET quantification in patients with 3-vessel coronary artery disease. J Nucl Cardiol 2004;11:440-9.
39. Yoshinaga K, Katoh C, Noriyasu K, et al. Reduction of coronary flow reserve in areas with and without ischemia on stress perfusion imaging in patients with coronary artery disease: a study using oxygen 15-labeled water PET. J Nucl Cardiol 2003;10:275-83.
40. Pitkänen O-P, Raitakari OT, Rönnemaa T, et al. Influence of cardiovarcular risk status on coronary flow reserve in healthy young men. Am J Cardiol 1997;79:1690-2.
41. Janatuinen T, Laaksonen R, Vesalainen R, et al. Effect of lipid-lowering therapy with pravastatin on myocardial blood flow in young mildly hypercholesterolemic adults. J Cardiovasc Pharmacol 2001;38:561- 8.
42. Tarakji KG, Brunken R, McCarthy PM, et al. Myocardial viability testing and the effect of early intervention in patients with advanced left ventricular systolic dysfunction. Circulation 2006;113:230- 7.
43. Allman KC, Shaw LJ, Hachamovitch R, et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002;39:1151-8.
44. Underwood SR, Bax JJ, vom Dahl J, et al. Imaging techniques for the assessment of myocardial hibernation. Report of a Study Group of the European Society of Cardiology. Eur Heart J 2004;25:815-36.
45. Kies P, Wichter T, Schafers M, et al. Abnormal myocardial presynaptic norepinephrine recycling in patients with Brugada syndrome. Circulation 2004;110:3017-22.
46. Pietila M, Malminiemi K, Ukkonen H, et al. Reduced myocardial carbon-11 hydroxyephedrine retention is associated with poor prognosis in chronic heart failure. Eur J Nucl Med 2001;28:373-6.
47. Neglia D, Michelassi C, Trivieri MG, et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 2002;105:186-93.
48. Shikama N, Himi T, Yoshida K, et al. Prognostic utility of myocardial blood flow assessed by N-13 ammonia positron emission tomography in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 1999;84:434-9.
49. Cecchi F, Olivotto I, Gistri R, et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003;349:1027-35
50. Gould KL, Martucci JP, Goldberg DI, et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease: a potential noninvasive marker of healing coronary endothelium. Circulation 1994;89:1530-8.
51. Baller D, Notohamiprodjo G, Gleichmann U, et al. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 1999;99:2871-5.
52. Huggins GS, Pasternak RC, Alpert NM, et al. Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse. Circulation 1998;98:1291-6.
53. Guethlin M, Kasel AM, Coppenrath K, et al. Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin. Circulation 1999;99:475-81.
54. Yokoyama I, Momomura S, Ohtake T, et al. Improvement of impaired myocardial vasodilatation due to diffuse coronary atherosclerosis in hypercholesterolemics after lipid-lowering therapy. Circulation 1999;100:117-22.
55. Tuunanen H, Engblom E, Naum A, et al. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 2006;114:2130-7.
56. Ukkonen H, Saraste M, Akkila J, et al. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 2000;68:522-31.
57. Sundell J, Engblom E, Koistinen J, et al. The effects of cardiac resynchronization therapy on left ventricular function, myocatdial energetics, and metabolic reserve in patients with dilated cardiomyopathy and heart failure. J Am Coll Cardiol 2004;43:1027-33.
58. Rudd JH, Warburton EA, Fryer TD, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002;105:2708-11.
59. Bengel FM, Anton M, Avril N, et al. Uptake of radiolabeled 2′-fluoro-2′-deoxy-5-iodo-1-beta-D-arabinofuranosyluracil in cardiac cells after adenoviral transfer of the herpesvirus thymidine kinase gene: the cellular basis for cardiac gene imaging. Circulation 2000;102:948-50.
60. Miyagawa M, Anton M, Wagner B, et al. Non-invasive imaging of cardiac transgene expression with PET: comparison of the human sodium/iodide symporter gene and HSV1-tk as the reporter gene. Eur J Nucl Med Mol Imaging 2005;32:1108-14.
61. Wu JC, Inubushi M, Sundaresan G, et al. Positron emission tomography imaging of cardiac reporter gene expression in living rats. Circulation 2002;106:180-3.
62. Wagner B, Anton M, Nekolla SG, et al. Noninvasive characterization of myocardial molecular interventions by integrated positron emission tomography and computed tomogtaphy. J Am Coll Cardiol 2006;48:2107-15.
63. Cao F, Lin S, Xie X, et al. In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery.Circulation 2006;113:1005-14.
64. Hofmann M, Wollert KC, Meyer GP, et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 2005;111:2198-202.
65. Yoshinaga K, Chow BJ, Williams K, et al. What is the prognostic value of myocardial perfusion imaging using rubidium-82 positron emission tomography? J Am Coll Cardiol 2006;48:1029-39.
66. Chow BJ, Wong JW, Yoshinaga K, et al. Prognostic significance of dipyridamole-induced ST depression in patients with normal 82Rb PET myocardial perfusion imaging. J Nucl Med 2005;46:1095-101.